Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
Introduction Low-cost generic direct-acting antiviral (DAA) regimens for treatment of hepatitis C virus (HCV) are available in several low-income/middle-income countries, important for treatment scale-up. This study evaluated the cost-effectiveness of genotype-dependent and pan-genotypic DAA regimen...
Saved in:
Main Authors: | Seyed Moayed Alavian, Mohammad Tasavon Gholamhoseini, Heidar Sharafi, Helena HL Borba, Asma Sabermahani, Behzad Hajarizadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/6/e058757.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
by: Yong-yu Mei, et al.
Published: (2020-01-01) -
Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
by: L. Tang, et al.
Published: (2018-01-01) -
Generic stabilizers for simple algebraic groups acting on orthogonal and symplectic Grassmannians
by: Aluna Rizzoli
Published: (2025-01-01) -
The Hsf1-sHsp cascade has pan-antiviral activity in mosquito cells
by: Jieqiong Qu, et al.
Published: (2025-01-01) -
Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study
by: Wencong Li, et al.
Published: (2022-01-01)